Apoptotic mechanisms in the control of erythropoiesis

Leukemia

Volumn 18, Issue 7, 2004, Pages 1176-1199

  Testa, U ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Anemia; Apoptosis; Erythropoiesis; Myelodysplasia; Myeloma

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; ERYTHROPOIETIN; FAS ANTIGEN; PROTEIN BCL XL; STAT5 PROTEIN; TRANSCRIPTION FACTOR GATA 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; PROTEIN;

ANEMIA; APLASTIC ANEMIA; APOPTOSIS; CELL DESTRUCTION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMING UNIT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; ENZYME ACTIVATION; ERYTHROCYTE; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; EVIDENCE BASED MEDICINE; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; MOLECULAR MECHANICS; MULTIPLE MYELOMA; MYELODYSPLASIA; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RETICULOCYTE; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; THALASSEMIA; HUMAN; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PHYSIOLOGY;

ANEMIA; APOPTOSIS; ERYTHROPOIESIS; HUMANS; MYELOPROLIFERATIVE DISORDERS; PROTEINS; SIGNAL TRANSDUCTION;

EID: 3142683813     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403383     Document Type: Review

References (207)

1. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BHU-F and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83: 59-67.
2. Wojchowski DM, Gregory RC, Miller CP, Pondit AK, Pircher TJ. Signal transduction in the erythropoietin system. Exp Cell Res 1999; 253: 143-156.
3. Testa U, Fossato C, Samoggia P, Mariani G, Hassan HJ, Sposi NM et al. Expression of growth factor receptors in unilineage differentiation culture of purified hematopoietic progenitors. Blood 1996; 88: 3391-3406.
4. Bauer A, Tronche F, Wessely O, Wellendonk C, Reichardt HM, Steinlein P et al. The glucocorticoid receptor is required for stress erythropoiesis. Genes Dev 1999; 13: 2996-3002.
5. Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene 2002; 21: 3368-3376.
6. Sposi NM, Zon LI, Carè A, Valtieri M, Testa U, Gabbianelli M et al. Cycle-dependent initiation and lineage-dependent abrogation of CATA-1 expression in pure differentiating hematopoietic progenitors. Proc Natl Acad Sci USA 1992; 89: 6353-6357.
7. Labbaye C, Valtieri M, Barberi T, Meccia E, Masella B, Pelosi E et al. Differential expression and functional role of GATA-2, NF-E2, and GATA-1 in normal adult hematopoiesis. J Clin Invest 1995; 95: 2346-2358.
8. Suzuchi N, Suwabe O, Obara N, Imagawa S, Pan X, Motohashi H et al. Identification and characterization of two types of erythroid progenitors that express GATA-1 at distinct levels. Blood 2003; 102:3575-3563.
9. Weiss MJ, Keller G, Orkin SH. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev 1994; 8: 1184-1197.
10. Weiss MJ, Orkin SH. Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. Proc Natl Acad Sci USA 1995; 92: 9623-9627.
11. L expression. Blood 1999; 94: 87-96.
12. Tsang AP, Fujiwara Y, Ham DB, Orkin SB. Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG. Genes Dev 1998; 12: 1176-1188.
13. Mikkola H, Klintman J, Hock H, Fujiwara Y, Orkin SH. Hematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem cell leukemia SCL/tal-1 gene. Nature 2003; 421: 547-551.
14. Gabbianelli M, Testa U, Massa A, Pelosi E, Sposi NM, Riccioni R et al. Hemoglobin switching in unicellular culture of sibling burstforming units: kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate. Blood 2000; 95: 3555-3561.
15. Green AR, DeLuca E, Begley CG. Antisense SCL suppresses self-renewal and enhances spontaneous erythroid differentiation of the human leukemic cell line K562. EMBO J 1991; 10: 4153-4158.
16. Valtieri M, Tocci A, Gabbianelli M, Lucchetti L, Masella B, Vitelli L et al. Enforced Tal-1 expression stimulates primitive erythroid and megakaryocytic progenitors but blocks the granulopoietic differentiation program. Cancer Res 1998; 58: 562-569.
17. Porcher C, Liao EC, Fuijwara Y, Zon LI, Orkin SH. Specification of hematopoietic and vascular development by the bHLH transcription factor SCL without direct DNA binding. Development 1999; 126: 4603-4615.
18. Levy DE, Darnell JF. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-662.
19. L induction. Cell 1999; 98: 181-191.
20. L gene expression by Stat5 in a bone marrow derived cell line. Oncogene 1999; 18: 4191-4199.
21. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, Kitamura T. Stat5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 1999; 18: 4754-4765.
22. Ariyoshi K, Nosaka T, Yamada K. Constitutive activation of Stat5 by a point mutation in the SH2 domain. J Biol Chem 2000; 275: 24407-24413.
23. Chida D, Miura O, Yoshimura A, Miyajima A. Role of cytokine signalling molecules in erythroid differentiation of mouse fetal liver cells: functional analysis of signalling molecules by retro-virus-mediated expression. Blood 1999; 93: 1567-1578.
24. -/- mice due to decreased survival of early erythroblasts. Blood 2001; 98: 3261-3273.
25. Kieslinger M, Woldman I, Moriggi R, Hofmann J, Marine JC, Ihle JN et al. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev 2000; 14: 232-244.
26. Joza N, Kroemer G, Penminger JM. Genetic analysis of the mammalian cell death machinery. Trends Genet 2002; 18: 142-149.
27. Kaufmann JH, Hengartner MD. Programmed cell death: alive and well in the new millennium. Trend Cell Biol 2001; 11: 526-534.
28. Vander Heiden MG, Thompson CB. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol 1999; 1: 209-216.
29. Kuwana T, MacKey MR, Perkins G, Ellisman M, Latterich M, Schneiter R et al. Bid, bax and lipids cooperate to for supramolecular openings in the outer mitochondrial membrane. Cell 2002; 111: 331-342.
30. Mursder VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Strasser A. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 2002; 419: 634-637.
31. Cory S, Adams JM. The Bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656.
32. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Negishi I et al. Massive cell death of immature hemopoietic cells and neurons in Bcl-X-deficient mice. Science 1995; 267: 1506-1510.
33. Motoyama N, Kimma T, Takahashi T, Watanabe T, Nakano T. Bcl-X prevents apoptotic cell death of both primitive and definitive erythrocytes at the end of maturation. J Exp Med 1999; 189: 1691-1698.
34. L gene from erythroid cells results in haemolytic anemia and profound splenomegaly. Development 2000; 127: 4949-4958.
35. L allows factor-indepenedent differentiation of primary erythroblasts. Curr Biol 2002; 12: 1076-1085.
36. Grillot D, Gonzalez-Garcia M, Ekhteral D, Duan L, Inohara N, Ohta S et al. Genomic organization, promoter region analysis, and chromosome localization of the mouse bcl-x gene. J Immunol 1997; 158: 4750-4757.
37. L through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999; 274: 22165-22169.
38. L expression. Blood 1999; 94: 87-96.
39. Tian C, Gregoli P, Bondurant M. Bcl-x promoter function in erythroid progenitor cells. Blood 2003; 101: 2235-2242.
40. Gregoli PA, Bondurant MC. Function of caspases in regulating apoptosis caused by erythropoietin deprivation in erythroid progenitors. J Cell Physiol 1998; 178: 133-143.
41. L/caspase-3 interaction. Circulation 2001; 103: 555-561.
42. L upregulation via inhibition of caspase activities in erythropoietin signalling. J Cell Physiol 2003; 195: 290-297.
43. Park JR, Bernstein ID, Hockenbery DM. Primitive human hematopoietic precursors express Bcl-X but not Bcl-2. Blood 1995; 86: 868-876.
44. Peters R, Leyvraz S, Perey L. Apoptotic regulation in primitive hematopoietic precursors. Blood 1998; 92: 2041-2052.
45. + hematopoietic progenitor cells induced to differentiate into erythroid or granulocytic cells. Stem Cells 2000; 18: 261-272.
46. Dolznig H, Boulmé F, Stangl K, Deiner EM, Mikulitis W, Beug H et al. Establishment of normal, terminally differentiating mouse erythroid progenitors: molecular characterization by cDNA arrays. FASEB J 2001; 15: 1442-1444.
47. L and apopain in the control of erythropoiesis by erythropoietin. Blood 19971; 90: 630-640.
48. L is required for heme synthesis during the chemical induction of erythroid differentiation of murine erythroleukemia cells independently of its anti-apoptotic function. Blood 2003; 101: 2575-2583.
49. L restrict lineage choice during hemopoietic differentiation. J Biol Chem 2003; 278: 25158-25165.
50. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272-4290.
51. Pahl HL. Towards a molecular understanding of polycythemia rubra vera. Eur J Biochem 2000; 267: 3395-3401.
52. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL. Expression of Bcl-X in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998; 338: 613-615.
53. Johnstone RW, Ruefli AA, Lowe JW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
54. L deamidation is a critical switch in the regulation of the response to DNA damage. Cell 2002; 111: 51-62.
55. Zeuner A, Pedini F, Signore M, Testa U, Pelosi E, De Maria R. Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via upregulation of Bcl-2 family proteins. Blood 2003; 102: 87-93.
56. Wang M, Tang D, Liu W, Chin K, Zhu J, Fibach E et al. Hydroxyurea exerts bi-modal dose-dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways. Br J Haematol 2002; 119: 1098-1105.
57. Ware CF. The TNF superfamily. Cytokine Growth Factor Rev 2003; 14: 181-184.
58. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. TRENDS Biochem Sci 2002; 27: 19-26.
59. Bhardway A, Aggarwal BB. Receptor-mediated choreography of life and death. J Clin Immunol 2003; 23: 317-332.
60. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Cancer Rev 2002; 2: 420-430.
61. Dempsey PW, Doyle SE, He JQ, Cheng G. The signalling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003; 14: 193-209.
62. Wang T, Zheng L, Lobito A, Chan F, Dale J, Sneller M et al. Inherited human caspase 10 mutation underlies defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999; 98: 47-58.
63. Kischkel FC, Lawrence M, LeBlanc H, Virmani A, Schaw P, Gordar A et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001; 276: 46639-46646.
64. Moldawer LL, Marano MA, Wei H, Fong Y, Silen ML, Kuo G et al. Cachetin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989; 3: 1637-1643.
65. Ulich TR, Del Castillo J, Yin S. Tumor necrosis factor exerts dose-dependent effects on erythropoiesis and myelopoiesis in vivo. Exp Hematol 1990; 18: 311-315.
66. Akahane K, Hosoi T, Urabe A, Kawakami M, Takakau F. Effects of recombinant human tumor necrosis factor (rhTNF) on normal human and mouse progenitor cells. Int J Cell Cloning 1987; 5: 16-26.
67. Means RT, Dessypris EN, Krantz SB. Inhibition of human colony-forming-unit erythroid by tumor necrosis factor requires accessory cells. J Clin Invest 1990; 86: 538-541.
68. Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Cin Invest 1993; 91: 416-419.
69. Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-α directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood 1995; 85: 989-997.
70. De Maria R, Zeuner A, Eramo A, Domenichelli C, Bonci D, Grignani F et al. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 1999; 401: 489-493.
71. Jacobs-Helber SM, Roh K, Bailey D, Dessypris EN, Ryan JJ, Chen J et al. 2003) Tumor necrosis factor-alpha expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia. Blood 2003; 101: 524-531.
72. + cells. Exp Hematol 2002; 30: 1238-1247.
73. Liu JJ, Hou SC, Shen CK. Erythroid gene suppressiion by NF-κB. J Biol Chem 2003; 278: 19534-19540.
74. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-795.
75. Schneider E, Mareau G, Arnould A, Vasseur F, Khodabaccus N, Dy M et al. Increased fetal and extramedullary hematopoiesis in Fas-deficient C57BL/6-lpr/lpr mice. Blood 1999; 94: 2613-2621.
76. Alenzi F, Marley SB, Lewis JL, Chandrasherkran A, Warrens AN, Goldman J et al. A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics. Exp Hematol 2002; 30: 1428-1435.
77. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T et al. In vitro expansion of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 1995; 86: 883-894.
78. Takenaka K, Nagafuji K, Harada M, Mizuno S, Miyamoto T, Makino S et al. In vitro expansion of hematopoietic progenitor cells induces functional expression of Fas antigen (CD95). Blood 1996; 88: 2871-2879.
79. Barcena A, Park SW, Bonapour B, Muench MO, Mechettner E. Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors isolated from human fetal liver. Blood 1996; 88: 2013-2022.
80. + human marrow cells is induced by interferon-γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995; 85: 3183-3190.
81. Bryder D, Ramsfjell V, Dybedal I, Borge DJ, Jacobsen SE. Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and Tumor Necrosis Factor activation. J Exp Med 2001; 194: 941-952.
82. + hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis. Stem Cells 2002; 20: 174-182.
83. Dai CH, Price JO, Brunnet T, Krantz SB. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon-γ to produce erythroid cell apoptosis. Blood 1998; 91: 1235-1242.
84. De Maria R, Testa U, Lucchetti L, Zeuner A, Stassi G, Pelosi F et al. Apoptotic role of Fas/Fas Ligand system in the regulation of erythropoiesis. Blood 1999; 93: 796-803.
85. Lee JW, Gersuk GM, Kiener PA, Beckam C, Ledbetter JA, Deeg HJ. HLA-DR-triggered inhibition of hemopoiesis involves Fas/Fas Ligand interactions and is prevented by c-kit ligand. J Immunol 1997; 59: 3211-3219.
86. Nishio M, Oda A, Koizuni K, Satoh I, Sawada K. Stem cell factor prevents Fas-mediated apoptosis of human erythroid precursor cells with Src-family kinase dependency. Exp Hematol 2001; 29: 19-29.
87. Chung IJ, Dai C, Krantz SB. Stem cell factor increases the expression of FLIP which inhibits IFN-γ induced apoptosis in human erythroid progenitor cells. Blood 2003; 101: 1324-1328.
88. Zeuner A, Eramo A, Testa U, Felli N, Pelosi E, Mariani G et al. Control of erythroid cell production via caspase-mediated cleavage of transcription factor SCL/Tal-1. Cell Death Diff 2003; 10: 905-913.
89. Secchiero P, Melloni E, Heikinheimo M, Mannito S, Di Pietro R, Iacone A et al. TRAIL regulates normal erythroid maturatioin through an ERK-dependent pathway. Blood 2003; 103: 517-522.
90. Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnemri ES et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000; 95: 3716-3724.
91. Hetakugas V, Poukkula M, Hetskanen KM, Kaninen JT, Sivtonen L, Eriksson JE. Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol Cell Biol 2003; 23: 1278-1291.
92. Daigle I, Yousefi S, Colonna M, Green DR, Simon HU. Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signalling in neutrophils. Nat Med 2002; 8: 61-67.
93. Long Q, Huang H, Shafizadeh E, Liu N, Lim S. Stimulation of erythropoiesis by inhibiting a new death receptor in transgenic zebrafish. Nat Cell Biol 2000; 2: 549-552.
94. Dai C, Krantz SB. Interferon-γ induces upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. Blood 1999; 93: 3309-3316.
95. Choi I, Muta K, Wickhema A, Krantz SB, Nishimura J, Nawata H. Interferon gamma delays apoptosis of mature erythroid progenitor cells in the absence of erythropoietin. Blood 2000; 95: 3742-3749.
96. Dallalio G, North M, Worden BD, Means RT. Inhibition of human erythroid colony formation by ceramide. Exp Hematol 1999; 27: 1133-1138.
97. Fsizaki Y, Jacobson MD, Raff MC. A role for caspases in lens fiber differentiation. J Cell Biol 1998; 140: 153-158.
98. Weil M, Raff MC, Braga VMM. Caspase activation in the terminal differentiation of human epidermal keratinocytes. Curr Biol 1999; 9: 361-364.
99. Sordet O, Rébé C, Plenchette S, Zermati Y, Hermine O, Vainchenker W et al. Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood 2002; 100: 4446-4453.
100. Botton S, Sabri S, Zermaty Y, Guidotti JE, Hermine O, Kroemer G et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002; 100: 1310-1317.
101. L overexpression in megakaryocytes leads to impaired platelet fragmentation. Blood 2002; 100: 1670-1678.
102. Gregoli PA, Bondurant MC. Function of caspases in regulating apoptosis caused by erythropoietin deprivation in erythroid progenitors. J Cell Physiol 1999; 178: 133-143.
103. Zermati Y, Garrido C, Amsellemn S, Fishelson S, Bouscary D, Valensi F et al. Caspase activation is required for terminal erythroid differentiation. J Exp Med 2001; 193: 247-254.
104. Kolbus A, Pilat S, Husak Z, Deiner EM, Stengl G, Beug H et al. Raf-1 antagonizes erythroid differentiation by restraining caspase activation. J Exp Med 2003; 196: 1347-1353.
105. Varfolomeev EE, Schuchmann M, Wallack D. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 1998; 9: 267-276.
106. Zhang J, Cando D, Chen A, Kobra N, Winoto A. Fas-mediated apoptosis and activation induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 1998; 392: 296-300.
107. Yeh WC, De La Pompo JL, Goeddel DV, Mak TW. FADD: essential for embryo development and signalling for some, but not all, induction of apoptosis. Science 1998; 279: 1954-1958.
108. Chun HJ, Zheng L, Strauss SF, Lenardo MJ. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 1998; 419: 395-399.
109. Peller S, Frenkel J, Lapidot T, Kahn J, Rahimi-Levene N, Youa R et al. The onset of p53-dependent apoptosis plays a role in terminal differentiation of human normoblasts. Oncogene 2003; 22: 4648-4655.
110. Weil M, Jacobson MD, Coles HSR, Davies TJ, Gardner RT, Raff KD et al. Constitutive expression of the machinery for programmed cell death. J Cell Biol 1997; 133: 1053-1059.
111. Weil M, Jacobson MD, Raft MC. Are caspases involved in the death of cells with a transcriptionally inactive nucleus? J Cell Sci 1998; 111: 2707-2715.
112. Bratosin D, Estaquier J, Petit F, Arnoult D, Montreuil J, Ameisen JC. Programmed cell death in mature erythrocytes: a model for investigating death effector pathways operating in the absence of mitochondria. Cell Death Diff 2001; 8: 1143-1156.
113. Mandel D, Maitre P, Saba S, Bosa J. Caspase 3 regulates phosphatilylserine extrenalization and phagocytosis of ox datively stressed erythrocytes. FEBS Lett 2002; 513: 184-188.
114. Berg CP, Engels IH, Rothbard A, Lauber K, Renz A, Schlosser JF et al. Human mature red blood cells express caspase-3 and caspase-8, but are devoid of mitochondrial regulators of apoptosis. Cell Death Diff 2001; 8: 1197-1206.
115. Mandal D, Baudin-Creuza V, Bhattacharyva A, Pathak S, Delaunay J, Kondu M et al. Caspase 3-mediated proteolysis of the N-terminal cytoplasmic domain of the human erythroid anion exchanger 1 (band3). J Biol Chem 2003; 278: 52551-52558.
116. Paw BH, Davidson AJ, Zhan Y, Lux SE, Fritz A, Postlethwait JH et al. Cell-specific mitotic defect and dyserythropoiesis associated with erythroid band 3 deficiency. Nat Genet 2003; 34: 59-64.
117. Aerbajinai W, Lee YT, Wojda U, Barr VA, Miller JL. Cloning and characterization of a gene expressed during terminal differentiation that encodes a novel inhibitor of growth. J Biol Chem 2004; 279: 1916-1921.
118. Kawane K, Fukuyama H, Kondoh G, Takeda J, Ohsawa Y, Uchiyama Y et al. Requirement of DNasell for definitive erythropoiesis in the mouse fetal liver. Science 2001; 292: 1546-1550.
119. Kriese RJ, Mac Lea KS, Longnecker DS, Fields JL, Flring S, Eastman A. Deoxyribonuclease II alpha is required during the phagocytic phase of apoptosis and its loss causes perinatal lethality. Cell Death Diff 2002; 9: 956-962.
120. Zhang J, Xu M. Apoptotic DNA fragmentation and tissue homeostasis. Trends Cell Biol 2002; 12: 84-89.
121. Vivanco I, Sawyers CL. The phosphatidyl-inositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
122. Nicholson KM, Anderson NG. The protein kinase B/AKT signalling pathway in human malignancy. Cell Signal 2002; 14: 381-395.
123. Djordjevic S, Driscoll PC. Structural insight into substrate specificity and regulatory mechanisms of phophoinositide 3-kinase. Trends Biochem Sci 2002; 27: 426-432.
124. Brazil DP, Park J, Hemmings BA. PKB binding proteins: getting in on the Akt. Cell 2002; 111: 293-303.
125. + cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 2002; 100: 2463-2471.
126. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Cancer Rev 2003; 3: 46-54.
127. Sui X, Krantz SB, You M, Zhao Z. Synergistic activation of MAP kinase (ERK 1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. Blood 1998; 92: 1142-1149.
128. Haseyama Y, Sawada KI, Oda A, Koizumi K, Takano H, Tarumi T et al. Phosphatidylinositol 3-kinase is involved in the protection of primary cultured human erythroid precursor cells from apoptosis. Blood 1999; 94: 1568-1577.
129. + hematopoietic progenitor cells. Exp Hematol 2002; 30: 990-1000.
130. Bouscary D, Pene F, Claessens YE, Muller O, Chrétien S, Fontenay-Roupie M et al. Critical role for PI 3Kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 2003; 101: 3436-3443.
131. Von Lindern M, Amelsvoort P, Van Dijk T, Deiner E, Akker E, De Vries S et al. Protein kinase C α controls erythropoietin receptor signalling. J Biol Chem 2000; 275: 34719-34727.
132. Burgering B, Kops G. Cell cycle and death control: long live Forkheads. Trends Biochem Sci 2002; 27: 352-360.
133. Dijkers PF, Birkenkamp K, Lam E, Thomay S, Lammers JW, Koenderman L et al. FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Sci 2002; 156: 531-542.
134. Kashil Y, Uchida M, Kirito K, Ozawa K, Komatsu N. A member of Forkhead family transcription factor, FKHRL1 is one of trghe downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood 2000; 96: 941-949.
135. Sommerville T, Linch D, Khwaja A. Growth factor withdrawal from primary human erythroid progenitors induced apoptosis through a pathway involving glycogen synthase kinase-3 and Bax. Blood 2001; 98: 1374-1381.
136. Jacobs-Helber S, Wickrema A, Birrer MJ, Sawyeer ST. AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells. Mol Cell Biol 2000; 18: 3699-3707.
137. Ketteler R, Maghraby CS, Hsiao JG, Sandra O, Lodish HF, Klingmuller U. The cytokine-inducible SH2 domain containing protein CIS negatively regulates signalling by promoting apoptosis in erythroid progenitor cells. J Biol Chem 2003; 278: 2654-2660.
138. Papadaky HA, Kritikos HD, Gemetzi C. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha (TNFα)-mediated effect. Blood 2002; 99: 1610-1619.
139. Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-α antibody therapy. Blood 2002; 100: 474-482.
140. Villurger A, Egle A, Marschitz I. Constitutive expression of Fas ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 1998; 90: 12-20.
141. Tucci M, Grinello D, Cafforio P, Silvestris F, Dammacco F. Anemia in multiple myeloma: role of deregulated plasma cell apoptosis. Leukem Lymphoma 2002; 43: 1527-1533.
142. Silvestris F, Tucci M, Cafforio P, Dammacco F. FasL up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood 2002; 97: 1155-1164.
143. + highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 2002; 99: 1305-1313.
144. Schrier SL. Pathophysiology of thalassemia. Curr Opin Hematol 2002; 9: 123-126.
145. Kihm AJ, Kong Y, Russell JE, Rouda S, Adachi K, Simon MC et al. An abundant erythroid protein that stabilizes free α -haemoglobin. Nature 2002; 417: 758-762.
146. Finch CA, Deubebeiss K, Cook JD. Ferrokinetics in man. Medicine 1970; 49: 17-53.
147. Yuan J, Angelucci E, Lucarelli G. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia). Blood 1993; 82: 374-377.
148. Centis F, Tabellini L, Lucarelli G, Angelucci E, Schrier SL. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with β-thalassemia major. Blood 2000; 96: 3624-3629.
149. Pootrakul P, Sirankapracha P, Hemsorach S, Moungsub W, Kumbunlue R, Piangitjagum A et al. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia. Blood 2000; 96: 2606-2612.
150. Mathias LA, Fisher TC, Zeug L, Meiselman HJ, Weinberg KI, Hit AL et al. Ineffective erythropoiesis in β-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. Exp Hematol 2000; 28: 1343-1353.
151. Angelucci E, Bai H, Centis F, Bafti MS, Lucarelli G, Ma L et al. Enhanced macrophagic attack on β-thalassemic major erythroid precursors. Haematologica 2000; 87: 578-583.
152. Messmer UK, Pfeilschfter J. New insights into the mechanism for clearance of apoptotic cells. BioEssays 2000; 22: 878-881.
153. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2002; 405: 89-92.
154. Koury MJ, Horne DW. Apoptosis mediates and thymidine prevents erythroblast destruction in folate deficiency anemia. Proc Natl Acad Sci USA 1994; 91: 4067-4071.
155. Koury MJ, Horne DW, Brown ZA, Pietenpol JA, Blount BC, Ames BN et al. Apoptosis of late-stage erythroblasts in megaloblastic anemia: association with DNA damage and macrocyte production. Blood 1997; 89: 4617-4623.
156. Koury MJ, Price JO, Hicks GG. Apoptosis in megaloblastic anemia occurs during DNA synthesis by a p53-independent, nucleoside-reversible mechanism. Blood 2000; 96: 3249-3255.
157. Ramos F, Fuertes-Nunez M, Vilela DS, Férnandez-Lopez A. What does apoptosis have to do with clinical features in myelodysplastic syndrome? Haematologica 2002; 87: 381-391.
158. Invernizzi R. The role of apoptosis in myelodysplastic syndromes. Haematologica 2002; 87: 337-346.
159. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268-276.
160. Gersuk GM, Lee JW, Beckam CA, Anderson J, Deeg HJ. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood 1996; 88: 1122-1123.
161. Bouscary D, De Vros J, Guesnu M, Jondeau K, Viguier F, Melle J et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997; 11: 839-845.
162. Gersuk GM, Beckam C, Loken MR, Kiener P, Anderson JE, Farrand A et al. A role for tumor necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998; 103: 176-188.
163. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002; 99: 1594-1601.
164. Schmidt-Mende J, Tehranci R, Forsblom AM, Joseph B, Christensson B, Fadeel B et al. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 2001; 15: 742-751.
165. Honikawa K, Nakakuma H, Kawaguchi T, Iwamoto N, Nagakura S, Kagimoto T et al. Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome. Blood 1997; 90: 2716-2722.
166. Sloand EM, Kim S, Fuhrer M, Risitano AM, Nakamura R, Maciejewski JP et al. Fas-mediated apoptosis is important in regulating
167. Zang Y, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001; 98: 3058-3065.
168. Tehranci R, Fadeel B, Forsblom AM, Christensson B, Samuelson J, Zhivotovsky B et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome C release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003; 101: 1080-1086.
169. Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Maushouri T et al. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 2003; 102: 1866-1868.
170. Bessho F, Ohnishi H, Tabuchi K, Kobayashi M, Hayashi Y. Significance of electron-dense deposits in the mitochondrial matrix of erythroid precursors in aplastic anaemia and myelodysplastic syndrome. Br J Haematol 1999; 105: 149-154.
171. Shin MG, Kajigaya S, Levin BC, Young NS. Mitochondrial DNA mutataions in patients with myelodysplastic syndromes. Blood 2003; 101: 3118-3125.
172. Perdhal EB, Naprstek BL, Wallace WC, Lipton JM. Erythroid failure in Diamond-Blackfan anemia is characterized by apoptosis. Blood 1994; 83: 645-650.
173. Hasegawa D, Kojima E, Hayakawa A, Kosaka Y, Nakamura H, Sako M et al. Elevation of the serum Fas ligand in patients with hematophagocytic syndrome and Dimanond-Blackfan anemia. Blood 1998; 91: 2793-2799.
174. Draptchinskaia N, Gustavsson P, Andersson B, Carlsson B, Dahl N. The gene encoding ribosomal protein S19 is mutataed in Diamond-Blackfan anemia. Nat Genet 1999; 21: 169-175.
175. Hamaguchi I, Ooka A, Bruin A, Richter J, Dahl N, Karlssonb S. Gene transfer improves erythroid development in ribosomal protein S19-deficient Diamond-Blackfan anemia. Blood 2002; 100: 2724-2731.
176. Da Costa L, Narla G, Willing T, Peters LL, Pana M, Fixler J et al. Ribosomal protein S19 expression during erythroid differentiation. Blood 2003; 101: 318-324.
177. Ahmad SI, Hanaoka F, Kirk SH. Molecular biology of Fanconi anemia: an old problem, a new insight. BioEssays 2002; 24: 439-448.
178. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Cancer Rev 2002; 3: 23-34.
179. Nakamishi K, Taniguchi T, D'Andrea AD. Interaction of FANC D2 and NBS1 in the DNA damage response. Nat Cell Biol 2002; 4: 913-920.
180. + cells of patients with aplastic anemia. Br J Haematol 1995; 91: 245-252.
181. Rathbun K, Faulkner GR, Ostroski MH, Tower PA, Bagby GC. Inactivation of the Fanconi anemia group C gene augments interferon-γ-induced apoptotic responses in hemopoietic cells. Blood 1997; 90: 974-985.
182. Ridet A, Guillouf C, Duchaud E, Cundari E, Fiore M, Moustacchi E et al. Deregulated apoptosis is a hallmark of the Fanconi anemia. Cancer Res 1997; 57: 1722-1730.
183. Wang J, Otsuki T, Youssoufian H, Foe JL, Kim S, Devetton M et al. Overexpression of the Fanconi anemia group C gene (FAC) protects hematopoietic progenitors from death induced by Fas-mediated apoptosis. Cancer Res 1998; 58: 3538-3541.
184. Otsuki T, Nagakura S, Wang J, Bloom M, grompe M, Liu JM. Tumor necrosis factor-α and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice. J Cell Physiol 1999; 179: 79-86.
185. Rathbun RK, Chistasor TA, Faulner GR. Interferon gamma-induced apoptotic responses of Fanconi anemia group C hematopoietic progenitors involve caspase-8 dependent activation of caspase 3 family members. Blood 2000; 96: 4204-4211.
186. Hadjun S, Jirik FR. Increased sensitivity of Fanc C deficient hematopoietic cells to nitric oxide and evidence that this species mediates growth inhibition by cytokines. Blood 2003; 101: 3877-3884.
187. Young NS. Acquired aplastic anemia. Ann Int Med 2002; 136: 534-546.
188. Killick SB, Cox CV, Marsch JC, Gordon-Smith EC, Gibson FM. Mechanisms of bone marrow progenitor cell apoptosis in aplastic anemia and the effect of anti-thymocyte globulin: examination of the role of the Fas-FasL interaction. Br J Haematol 2000; 111: 1164-1169.
189. Luther-Wirsch A, Nissen C, Wodnar-Filipowicz A. Intracellular Fas ligand is elevated in T lymphocytes in severe aplastic anemia. Brit J Haematol 2001; 114: 884-892.
190. Zeng W, Chen G, Kajigaya S, Nunez O, Charrow A, Billings AM et al. Gene expression profiling in CD34 cells identifies significant differences between aplastic anemia patients and health volunteers. Blood 2004; 103: 325-332.
191. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Post-transplant erythrocytosis. Kidney Int 2003; 63: 1187-1194.
192. Volpe M, Tritto C, Testa U. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic and hormonal profile. Am J Cardiol 1994; 74: 468-473.
193. Vlahakos DV, Kosmas EN, Domopulou I. Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am J Med 1999; 106: 158-164.
194. Vlahakos DV, Marathias KP, Kosmas EN. Losortan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis. Ann Int Med 2001; 134: 426-427.
195. Hudgson P, Pearse JM, Yeates WK. Renal artery stenosis with hypertension and high hematocrit. Br J Med 1967; 1: 18-21.
196. Bourgognie JJ, Gallagher NI, Perry HM. Renin and erythropoietin in normotensive and in hypertensive patients. J Lab Clin Med 1968; 71: 523-536.
197. Labeeuw M, Prost NF, Daoub S. Renal venous erythropoietin concentrations in hypertensive patients with unilateral renal disease. Nephrol Dial Transplant 1992; 7: 1190-1193.
198. Vlahakos DV, Balodimos C, Papachristopoulos V. Renin-angiotensin system stimulates erythropoietin secretion in chronic hemodialysis patients. Clin Nephrol 1995; 43: 53-59.
199. Onoyama K, Sanai T, Motomura K, Fujishima M. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J Cardiovasc Pharmacol 1989; 13: S27-S30.
200. Mrug M, Stopka T, Jukkian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proiliferation of normal early erythroid progenitors. J Clin Invest 1997; 100: 2310-2314.
201. Cole J, Ertoy D, Lin H, Sutiliff R, Ezan E, Guyene T et al. Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting anzyme-deficient mice. J Clin Invest 2000; 106: 1391-1398.
202. Glicklich D, Burris L, Urban A, Tellis V, Greenstein S, Schechner R et al. Angiotensin-convertin enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis. J Am Soc Nephrol 2001; 12: 1958-1964.
203. Glazerman I, Patel H, Glicklich D, Croizat H, Devarajan P. Angiotensin-converting enzyme inhibition induces death receptor apoptotic pathways in erythroid precursors following renal transplantation. Am J Nephrol 2003; 23: 195-201.
204. Beutler E. Production and destruction of erythrocytes in Williams. Textbook of Hematology. McGraw-Hill: USA 2001, 355-358.
205. Khaled AR, Durum SK. Lymphocyde: cytokines and the control of lymphoid homeostasis. Nat Rev Immunol 2002; 2: 817-830.
206. Rathmell JC, Thompson CB. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 2002; 109: 97-107.
207. Coletti D, Yang E, Marazzi G, Sassoon D. TNFα inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J 2002; 21: 631-642.